Partner, The Column Group
Dr. Chen joined The Column Group in 2019. Previously, he was a Venture Partner at OrbiMed focusing on company creation and investing in early stage biotech companies. In this capacity he took on interim management roles at E-Scape Bio, TranscripTx (now ReCode) and Adicet. Prior to that Dr. Chen was a Partner at Skyline Ventures and an entrepreneur in residence at Venrock. He current sits on the boards of Eikon, TR1X, Velia, Sastra and Lyterian.
Dr. Chen started his career in 2002 as a founder of KAI Pharmaceuticals, which was acquired by Amgen in 2012 and led to the approval of Parsabiv in US, Europe, and Japan. He earned his BA in Biochemistry from UC Berkeley, PhD in Molecular Pharmacology from Stanford School of Medicine, and MBA from Stanford Graduate School of Business.